非小细胞肺癌铂类化疗药物基因组学研究  

The pharmacogenomics of platinum chemotherapy in non-small cell lung cancer

作　　者：崔佳佳[1] 尹继业[1] 

机构地区：[1]中南大学湘雅医学院临床药理研究所遗传药理学湖南省重点实验室,湖南长沙410078

出　　处：《转化医学杂志》2014年第5期291-297,共7页Translational Medicine Journal

基　　金：国家自然科学基金(81202595)

摘　　要：基于铂类的联合化疗是当前非小细胞肺癌(non-small-cell lung cancer,NSCLC)治疗的主要途径之一,而不同患者的临床疗效差异较大。遗传因素是影响NSCLC铂类化疗疗效的重要因素之一,大量DNA损伤与修复、药物代谢与解毒、细胞周期和凋亡、药物转运体与膜受体相关基因的变异都可以影响NSCLC铂类化疗药物化疗敏感性。本文将对上述内容进行系统全面的总结,并探讨建立准确预测NSCLC铂类化疗疗效的药物基因组学模型的可能性。Platinum-based chemotherapy is one of the major treatment methods for non-small-cell lung cancer (NSCLC), however, the therapeutic efficiency varies largely among different pa-tients.Genetic variation is one of the most important factors influencing NSCLC patients platinum-based chemotherapy, lots of gene mutations related to DNA damage and repair, drug metabolism and detoxification, cell cycle and apoptosis, drug transporter and membrane receptor were associated with response to platinum-based chemotherapy.In this review, the recent progress of pharmaco-genomics of platinum chemotherapy in NSCLC was systematically summarized, and also the possibility of establishing a pharmacogenomics model for accurately predicting platinum-based chemotherapy efficacy of NSCLC patients will be discussed.

关 键 词：非小细胞肺癌 铂类 化疗 药物基因组学 耐药 单核苷酸多态性 

分 类 号：R734.2[医药卫生—肿瘤] R979.19[医药卫生—临床医学]